Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04463771
Title Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. (POD1UM-204)
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements Yes
Sponsors Incyte Corporation
Indications

endometrial cancer

Therapies

Pemigatinib + Retifanlimab

Epacadostat + Retifanlimab

Retifanlimab

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST